Human Papillomavirus (HPV) Vaccine

Safety Information

About HPV Infection

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. Most infections are asymptomatic and become undetectable, but some can be persistent and can progress to cancer in both women and men later in life. Learn more about HPV

There is a safe and effective HPV vaccine. CDC recommends HPV vaccination for all boys and girls at ages 11-12 to protect against HPV-related infections and cancers.

Some adults age 27 through 45 years who are not already vaccinated may decide to get HPV vaccine after speaking with their doctor about their risk for new HPV infections and the possible benefits of vaccination. HPV vaccination in this age range provides less benefit, as more people have already been exposed to HPV.

Vaccine Information Statements

Vaccine Information Statements (VISs) are information sheets produced by CDC that explain both the benefits and risks of a vaccine.

  • HPVHuman papillomavirus vaccine (Gardasil 9)

Available Vaccine and Package Insert

There is one licensed HPV vaccine available in the United States:

Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant; 9vHPV) was approved by FDA for use in 2014. The safety of Gardasil 9 was studied in clinical trials with more than 15,000 participants before it was licensed and continues to be monitored. Gardasil 9 protects against 9 types of cancer-causing HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.

CDC recommends that anyone starting the series before their 15th birthday receives two doses of HPV vaccine, with at least six months between the first and second dose. Adolescents who receive their two doses less than five months apart will require a third dose of HPV vaccine.Teens and young adults who start the series at ages 15 through 26 years still need three doses of HPV vaccine.  Also, three doses are recommended for people with certain immunocompromising conditions aged 9 through 26 years.

calendar alt icon

Child and Adult Immunization Schedules
Get CDC’s official recommended immunization schedules for children, adolescents, and adults.

Manufacturer Package Insert

Gardasil 9 [PDF – 25 pages]external icon:
The Food and Drug Administration (FDA) approved this vaccine in 2014. It is approved for use in children at age 9.

Common Side Effects

HPV vaccine is safe and effective at preventing HPV-related infections and cancers. Vaccines, like any medicine, can have side effects. Many people who get the HPV vaccine have no side effects at all. The most common side effects are usually mild, like a sore arm from the shot.


Severe allergic reactions following vaccination are rare, but can be life threatening.
Symptoms of a severe allergic reaction may include hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, and weakness.

If such reactions occur, seek immediate medical attention.

HPV Vaccine (Gardasil 9)

Common Side Effects 

  • Pain, redness, or swelling in the arm where the shot was given
  • Fever
  • Headache or feeling tired
  • Nausea
  • Muscle or joint pain

Who Should Not Get the HPV Vaccine

Tell your vaccine provider if the person getting the vaccine:

  • Has had an allergic reaction after a previous dose of HPV vaccine, or has any severe, life-threatening allergies.
  • Is pregnant.

In some cases, your healthcare provider may decide to postpone HPV vaccination to a future visit.

People with minor illnesses, such as a cold, may be vaccinated. People who are moderately or severely ill should usually wait until they recover before getting HPV vaccine.

More Information

A Closer Look at the Safety Data

Findings from many vaccine safety monitoring systems and more than 160 studies have shown that HPV vaccines have a favorable safety profile—the body of scientific evidence overwhelmingly supports their safety.

  • In November 2019, initial post-licensure safety monitoring of Gardasil 9 was published in Pediatrics. In two separate articles, analyses from the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD) were presented. Both included multiple years of data, and did not identify any unexpected safety problems with Gardasil 9. These findings support the favorable safety profile that was established in pre-licensure clinical trials.
    • Analysis from VAERS: Researchers reviewed 7,244 reports submitted to the Vaccine Adverse Event Reporting System following HPV vaccination from December 2014 through December 2017. Of those reports, around 97% were classified as non-serious; around 3% were considered serious. The analysis did not detect any new or unexpected safety concerns.
    • Analysis from VSD: The Vaccine Safety Datalink conducted near-real time surveillance from October 2015 through October 2017, looking at 11 pre-specified adverse events. During this two-year time period, nearly 840,000 doses were administered to people aged 9-26 years at six VSD sites. No new safety concerns were identified.
  • In 2014, before Gardasil 9 was licensed by the FDA, its safety was evaluated across seven studies. The safety findings from these pre-licensure studies show that Gardasil 9 has a similar safety profile to Gardasil, an earlier version of the vaccine. The main findings from these studies:
    • The most common side effect reported was pain, swelling, and redness in the arm where the shot was given.
    • These mild side effects may occur more often after Gardasil 9 vaccination than after Gardasil. Women and girls who received Gardasil 9 reported higher rates of swelling and redness where the shot was given than those who received Gardasil. Reports of swelling and redness also increased with each following dose for those receiving Gardasil 9.
  • In 2014, CDC published a report analyzing health events reported to VAERS following Gardasil vaccination from June 2006 through March 2014. About 92% of the Gardasil reports were classified as non-serious.
    The most common adverse events reported were:
    • Syncope (fainting)
    • Dizziness
    • Nausea
    • Headache
    • Fever
    • Injection site reactions (pain, swelling, and redness)

    Although rare, fainting was found to happen after HPV vaccination. In response, FDA changed Gardasil’s guidance for doctors to include information about preventing falls and injuries from fainting. CDC and the Advisory Committee on Immunization Practices included this guidance in the recommendations for HPV vaccination. Based on these recommendations, healthcare professionals should administer HPV vaccinations while the patient is seated or lying down.
    The patient should then remain seated and be observed for 15 minutes. CDC continues to remind doctors and nurses to observe this guidance and to share this information with all their patients.

  • In 2011, the Institute of Medicine (IOM) reviewed published and unpublished studies of the safety of eight vaccines, including HPV. The published report, Adverse Effects of Vaccines: Evidence and Causalityexternal icon, concluded:
    • Syncope (fainting) may be caused by injected vaccines, including HPV vaccines.

    Very rarely, any vaccine, including HPV vaccine, can cause anaphylaxis. Some people are allergic to certain ingredients in vaccines. As recommended by ACIP, people who experienced a severe allergic reaction (e.g., anaphylaxis) to a previous vaccine dose or to a vaccine component, including yeast, should not receive the HPV vaccine.

Which adverse events are considered “serious”?

By regulation, an adverse event is defined as seriousexternal icon if it involves any of the following outcomes:

  • death
  • a life-threatening adverse event
  • a persistent or significant disability or incapacity
  • a congenital anomaly or birth defect
  • hospitalization, or prolongation of existing hospitalization

How CDC Monitors the Safety of HPV Vaccines

CDC and FDA monitor the safety of vaccines after they are approved. If a problem is found with a vaccine, CDC and FDA will inform health officials, health care providers, and the public.

CDC uses three systems to monitor vaccine safety:

Related Scientific Articles

Donahue JG, Kieke BA, Lewis EM, Weintraub ES, Hanson KE, McClure DL, Vickers ER, Gee J, Daley MF, DeStefano F, Hechter RC, Jackson LA, Klein NP, Naleway AL, Nelson JC, Belongia EA.  Near Real-Time Surveillance to Assess the Safety of the 9-valent Human Papillomavirus Vaccineexternal icon. Pediatrics. 2019 Nov 18. 144(5): e20191808

Shimabukuro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV. Safety of the 9-valent human papillomavirus vaccine.external icon Pediatrics. 2019 Nov 18. 144(5): e20191791

Hanson KE, McLean HQ, Belongia, EA, Stokley S, McNeil MM, Gee J, VanWormer JJ. Sociodemographic and clinical correlates of human papillomavirus vaccine attitudes and receipt among Wisconsin adolescentsexternal icon. Papillomavirus. Res. 2019 May 25; 8: 1001568. Epub ahead of print.

Klein NP, Goddard K, Lewis E, Ross P, Gee J, DeStefano F, Baxter R. Long term risk of developing type 1 diabetes after HPV vaccination in males and femalesexternal icon. Vaccine. 2019 Mar 28; 37(14): 1938-1944. Epub Mar 1.

Landazabal CS, Moro PL, Lewis P, Omer SB. Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017external icon. Vaccine. 2019 Feb 21; 37(9): 1229-1234. Epub 2019 Jan 16.

Suragh TA, Lewis P, Arana J, Mba-Jonas A, Li R, Stewart B, Shimabukuro TT, Cano M. Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017.external iconexternal icon Br J Clin Pharmacol. 2018 Dec; 84(12): 2928-2932. Epub 2018 Sep 21.

Naleway AL, Mittendorf KF, Irving, SA, Henninger ML, Crane B, Smith N, Daley MF, Gee J. Primary Ovarian Insufficiency and Adolescent Vaccination. external icon Pediatrics. 2018 Sep; 142(3). Epub 2018 Aug 21.

Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Sheth SS, Zhu J, Naleway AL, Klein NP, Hechter R, Daley MF, Donahue JG, Jackson ML, Kawai AT, Sukumaran L, Nordin JD. Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancyexternal icon. Obstet. Gynecol. 2018 Jul; 132(1): 35-44.

Irving SA, Groom HC, Stokley S, McNeil MM, Gee J, Smith N, Naleway AL. Human Papillomavirus Vaccine Coverage and Prevalence of Missed Opportunities for Vaccination in an Integrated Healthcare Systemexternal icon. Acad. Pediatr. 2018 Mar; 18(2S): S85-S92.

Markowitz LM, Gee J, Chesson H, Stokley S. Ten Years of Human Papillomavirus Vaccination in the United States. external icon Acad. Pediatr. 2018 Mar; 1(2S): S3-S10.

Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015external icon. Vaccine. 2018 Mar 20; 36(13): 1781-1788. Epub 2018 Feb 21.

Arana J, Mba-Jonas A, Jankosky C, Lewis P, Moro PL, Shimabukuro TT, Cano M. Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting Systemexternal iconexternal icon. J Adolesc Health. 2017 Nov; 61(5): 577-582.

VanWormer JJ, Bendixsen CG, Vickers ER et al. Association between parent attitudes and receipt of human papillomavirus vaccine in adolescentsexternal icon. BMC Public Health. 2017 Oct 2; 17(1): 766.

Gee J, Sukumaran L, Weintraub E. Risk of Guillain-Barre Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalinkexternal icon. Vaccine. 2017 Oct 13; 35(43): 5756-5758. Epub 2017 Sep 19.

Lipkind HS, Vazquez-Benitez G, Nordin JD et al. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancyexternal icon. Obstet Gynecol. 2017 Sep; 130(3): 599-608.

McLean HQ, VanWormer JJ, Chow BDW et al. Improving Human Papillomavirus Vaccine Use in an Integrated Health System: Impact of a Provider and Staff Interventionexternal icon. J Adolesc Health. 2017 Aug; 61(2): 252-258. Epub 2017 Apr 24.

Baxter R, Lewis E, Goddard K et al. Acute demyelinating events following vaccines – a case centered analysis.external icon Clin Infect Dis. 2016 Dec 1; 63(11): 1456-1462. Epub 2016 Sep 1.

Baxter R, Lewis E, Fireman B, DeStefano F, Gee J, Klein NP. Case-centered analysis of Optic Neuritis following vaccines.external icon  Clin Infect Dis. 2016 Jul 1; 63(1): 79-81. Epub 2016 Apr 10.

Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and US safety monitoring plans for nine-valent HPV vaccineexternal icon. Hum Vaccin Immunother. 2016 Jun 2; 12(6): 1406-17. Epub 2016 Mar 30.

McCarthy NL, Gee J, Sukumaran L et al. Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adultsexternal icon. Pediatrics. 2016 Mar; 137(3): e20152970. Epub 2016 Feb 1.

Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, et al. Safety of quadrivalent human papillomavirus vaccine (Gardasil®) in pregnancy: Adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013external icon. Vaccine. 2015 Jan 15; 33(4): 519-22. Epub 2014 Dec 8.

Naleway AL, Crane B, Smith N et al. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011external icon. Vaccine. 2016 Jan2; 34(1): 167-71. Epub 2015 Nov 6.

Weinbaum CM, Cano M.  HPV vaccination and Complex Regional Pain Syndrome:  Lack of Evidence. external iconEbiomedicine. 2015 Aug 19; 2(9): 1014-5. eCollection 2015 Sep.

Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-Valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR. 2015; 64(11):300-304.

Gee J, Naleway A, Shui I et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalinkexternal iconVaccine. 2011 Oct 26; 29(46): 8279-84. Epub 2011 Sep 9.

Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccineexternal icon. JAMA. 2009 Aug 19; 302(7): 750-7.

Stokley S, Curtis CR, Jeyarajah J, Harrington T, Gee J, Markowitz L.  Human papillomavirus vaccination coverage among adolescent girls 2007-2012, and post-licensure vaccine safety monitoring 2006-2013-United Statesexternal icon. MMWR Morb Mortal Wkly Rep. 2013 Jul 26; 62(29): 591-595.

Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L.  Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014—United States.external icon MMWR Morb Mortal Wkly Rep. 2014 Jul 25; 63(29): 620-4.

Naleway AL, Gold R, Drew L, et al. Reported adverse events in young women following quadrivalent human papillomavirus vaccinationexternal iconJ Womens Health (Larchmt.). 2012 Apr; 21(4): 425-32. Epub 2012 Jan 9.

Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2014; 63(RR05);1-30.

Gold R, Naleway A, Riedlinger K. Factors predicting completion of the human papillomavirus vaccine seriesexternal iconJ Adolesc Health. 2013 Apr; 52(4): 427-32. Epub 2012 Dec 10.

Schmidt MA, Gold R, Kurosky SK, et al. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink, July 2006-June 2011external iconJ Adolesc Health. 2013 Nov; 53(5): 637-41.

Gee J, Naleway A, Shui I, Baggs J, Yinc R, Lic R, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalinkexternal icon, Vaccine. 2011; 29 (46) 8279-8284.

Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua J, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. external icon JAMA. 2009; 302 (7):750-7.